Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
GlaxoSmithKline will pay $680 million in cash for the commercial operations and distribution rights for UCB's marketed product portfolio in certain parts of Africa, the Middle East, Asia-Pacific, and Latin America. The deal gives GSK rights to sell the epilepsy drug Keppra and the allergy drugs Xyzal and Zyrtec, among other drugs. It also ties into GSK's recently launched strategy to strengthen its position in emerging markets, which the company says will represent 40% of growth in pharmaceuticals by 2020, in order to reduce its reliance on blockbuster drugs.
This article has been sent to the following recipient: